# SGLT2i in Kidney Stones

> **NCT07055282** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Chicago** · enrollment: 32 (estimated)

## Conditions studied

- Kidney Stones

## Interventions

- **DRUG:** Empagliflozin (Jardiance®)

## Key facts

- **NCT ID:** NCT07055282
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07055282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07055282, "SGLT2i in Kidney Stones". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT07055282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*